Robert Ghenchev
Direttore/Membro del Consiglio presso OXFORD BIOMEDICA PLC
Posizioni attive di Robert Ghenchev
Società | Posizione | Inizio | Fine |
---|---|---|---|
OXFORD BIOMEDICA PLC | Direttore/Membro del Consiglio | 24/06/2019 | - |
EXSCIENTIA PLC | Direttore/Membro del Consiglio | 01/05/2020 | - |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Direttore/Membro del Consiglio | 01/01/2018 | - |
Gestore di Portafoglio-Azioni | 01/01/2021 | - | |
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investitore di Private Equity | 01/01/2018 | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | 01/05/2020 | - |
Mission Bio, Inc.
Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - | - |
Mightyowl, Inc. | Direttore/Membro del Consiglio | - | - |
Novo Holdings Equity Us, Inc. | Corporate Officer/Principal | - | - |
Quanta Dialysis Technologies, Inc. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Robert Ghenchev
Precedenti posizioni note di Robert Ghenchev
Società | Posizione | Inizio | Fine |
---|---|---|---|
░░░░░░ ░ ░░░ ░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Robert Ghenchev
McGill University | Undergraduate Degree |
University of Oxford | Graduate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 6 |
Stati Uniti | 6 |
Danimarca | 3 |
Posizioni
Director/Board Member | 8 |
Corporate Officer/Principal | 2 |
Portfolio Manager-Equities | 1 |
Settori
Finance | 4 |
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
OXFORD BIOMEDICA PLC | Health Technology |
Technology Services | |
EXSCIENTIA PLC | Health Technology |
Aziende private | 8 |
---|---|
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Finance |
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Moelis & Co. (UK) LLP
Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010. | Finance |
Mission Bio, Inc.
Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Commercial Services |
Mightyowl, Inc. | |
Novo Holdings Equity Us, Inc. | |
Quanta Dialysis Technologies, Inc. |
- Borsa valori
- Insiders
- Robert Ghenchev
- Esperienza